Deferiprone: all 43 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in SchizophreniaRecruitingNCT07759895Phase 2
• Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruitingNCT07023666Phase 2
• Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction PatientsRecruitingNCT05604131Phase 2
• Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young ChildrenCompletedNCT03591575Phase 4Results posted
• Study of Parkinson's Early Stage With DeferiproneCompletedNCT02728843Phase 2Results posted
• Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy VolunteersCompletedNCT02465489Phase 1Results posted
• Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02443545Phase 4Results posted
• Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy VolunteersCompletedNCT02442310Phase 1Results posted
• Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy VolunteersCompletedNCT02189941Phase 1Results posted
• Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated NeurodegenerationCompletedNCT02174848Phase 3Results posted
• Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other AnemiasTerminatedNCT02041299Phase 4Results posted
• A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy VolunteersCompletedNCT01989455Phase 1Results posted
• Evaluation of Whether Deferiprone Affects QT Interval in Healthy SubjectsCompletedNCT01860703Phase 4Results posted
• Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric PatientsCompletedNCT01825512Phase 3Results posted
• An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal ImpairmentCompletedNCT01770652Phase 4Results posted
• An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy VolunteersCompletedNCT01767103Phase 4Results posted
• Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)CompletedNCT01741532Phase 3Results posted
• Combination Deferasirox and Deferiprone for Severe Iron Overload in ThalassemiaCompletedNCT01709032Phase 1/2Results posted
• A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedNCT01539837Phase 2Results posted
• Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric PatientsCompletedNCT00529152Phase 3Results posted
• Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral SclerosisCompletedNCT03293069Phase 2/3
• Deferiprone to Delay Dementia (The 3D Study)CompletedNCT03234686Phase 2
• Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose AdministrationCompletedNCT02980458Phase 1
• Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating LymphocytesCompletedNCT02880033Not applicable
• A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive ImpairmentWithdrawnNCT02878538Early Phase 1
• Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's DiseaseCompletedNCT02655315Phase 2
• Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS PatientsCompletedNCT02477631Phase 2
• Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive SubjectsCompletedNCT02456558Phase 1
• Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected SubjectsCompletedNCT02191657Phase 1
• An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major PatientsStatus unknownNCT02173951Phase 2/3
• Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) PatientsCompletedNCT02164253Phase 2
• Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)Status unknownNCT01996683Not applicable
• Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E PatientsCompletedNCT01597765Not applicable
• Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron OverloadStatus unknownNCT01511848Phase 2/3
• Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast AgentWithdrawnNCT01391520Phase 3
• Efficacy and Safety of the Iron Chelator Deferiprone in Parkinson's DiseaseCompletedNCT00943748Phase 2/3
• Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)Status unknownNCT00907283Phase 2
• A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's AtaxiaCompletedNCT00897221Phase 2
• Efficacy Study of the Use of Sequential DFP-DFO Versus DFPCompletedNCT00733811Phase 4
• A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's AtaxiaCompletedNCT00530127Phase 1/2
• Study With Deferiprone and/or Desferrioxamine in Iron Overloaded PatientsCompletedNCT00350662Phase 3
• Efficacy Study in Removing Excess Iron From the HeartCompletedNCT00105495Phase 4
• Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia MajorStatus unknownNCT00103753Phase 4

← Deferiprone overview